Nasopharyngeal Nonkeratinizing Carcinoma
2 clinical trials · Condition
◉ Watch Nasopharyngeal Nonkeratinizing Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer (NCT04458909) | National Cancer Institute (NCI) | 2020-12-09 |
| Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer (NCT02339558) | National Cancer Institute (NCI) | 2015-07-21 |
Track Nasopharyngeal Nonkeratinizing Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.